In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
May 9th, 2008 | 24 | Yes |
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.37 | 7.5 | -14.6 | 1 | 4 | 0 | 39 | 319.408 | 3 | ↓ |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
MK14-2-E | MAP Kinase P38 Alpha (cluster #2 Of 3), Eukaryotic | Eukaryotes | 1540 | 0.34 | Binding ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 1540 | 0.34 | Binding ≤ 10μM |
Description | Species |
---|---|
activated TAK1 mediates p38 MAPK activation | |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
Activation of the AP-1 family of transcription factors | |
ADP signalling through P2Y purinoceptor 1 | |
CDO in myogenesis | |
DSCAM interactions | |
ERK/MAPK targets | |
KSRP destabilizes mRNA | |
NOD1/2 Signaling Pathway | |
Oxidative Stress Induced Senescence | |
p38MAPK events | |
Platelet sensitization by LDL | |
VEGFA-VEGFR2 Pathway |